Scpharmaceuticals ( (SCPH) ) has released its Q2 earnings. Here is a breakdown of the information Scpharmaceuticals presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
scPharmaceuticals Inc., a pharmaceutical company focused on advancing cardiorenal care through patient-centric innovations, has reported its financial results for the second quarter of 2025. The company, headquartered in Burlington, Massachusetts, is known for its innovative solutions in the healthcare sector, particularly in the treatment of chronic heart failure and chronic kidney disease.
In the second quarter of 2025, scPharmaceuticals achieved a significant milestone with net revenue of $16 million, marking a 99% increase compared to the same period in 2024. This growth is attributed to the increased adoption of FUROSCIX, a treatment for edema in patients with chronic heart failure and chronic kidney disease. The company also launched FUROSCIX for chronic kidney disease, expanding its market reach.
Key financial highlights include a 117% increase in doses shipped compared to the second quarter of 2024, and a 70% rise in sales to Integrated Delivery Networks over the first quarter of 2025. Despite these achievements, the company reported a net loss of $18 million for the quarter, reflecting increased costs in research and development, as well as selling, general, and administrative expenses.
Looking forward, scPharmaceuticals remains optimistic about its growth trajectory. The company is on track to submit a supplemental New Drug Application for its 80mg/1mL FUROSCIX Autoinjector, which is expected to significantly reduce administration time. Management is also hopeful about the potential benefits of the proposed Ambulatory Specialty Model by the Centers for Medicare and Medicaid Services, which could enhance the adoption of FUROSCIX in the market.